{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:35:15Z","timestamp":1790876115934,"version":"4.1.0"},"reference-count":140,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The ERK1\/2 and PI3K signaling pathways play important roles in cellular proliferation, survival, differentiation, and metabolism. In cancer, these pathways are frequently dysregulated and overactivated, resulting in poor patient prognosis and resistance to treatment. These pathways are activated by receptor tyrosine kinases and send downstream signals to effectors such as RAS, RAF, MEK, AKT, and mTOR. In this review, we highlight the key components of the ERK1\/2 and PI3K pathways, the roles they play in tumor progression, and the development of inhibitors and combination therapies designed to enhance therapeutic outcomes and address treatment resistance. Our review demonstrates the need and promise for future research and clinical trials for inhibitors and combination therapies for the ERK1\/2 and PI3K pathways in cancer.<\/jats:p>","DOI":"10.3390\/ijms26178696","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:27:12Z","timestamp":1757500032000},"page":"8696","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Current and Emerging Therapies for Targeting the ERK1\/2 &amp; PI3K Pathways in Cancer"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6467-2738","authenticated-orcid":false,"given":"Ethan","family":"Abizadeh","sequence":"first","affiliation":[{"name":"College of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Berglas","sequence":"additional","affiliation":[{"name":"College of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Abizadeh","sequence":"additional","affiliation":[{"name":"Zucker School of Medicine, Hofstra University, Hempstead, NY 11549, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Glatman","sequence":"additional","affiliation":[{"name":"College of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron B.","family":"Lavi","sequence":"additional","affiliation":[{"name":"College of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Spivak","sequence":"additional","affiliation":[{"name":"College of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1689-2176","authenticated-orcid":false,"given":"Tzuriel","family":"Sapir","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4108-4664","authenticated-orcid":false,"given":"David","family":"Shifteh","sequence":"additional","affiliation":[{"name":"College of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","article-title":"ERK signalling: A master regulator of cell behaviour, life and fate","volume":"21","author":"Lavoie","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: Are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3390\/cancers7030860","article-title":"Targeting RTK Signaling Pathways in Cancer","volume":"7","author":"Regad","year":"2015","journal-title":"Cancers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: From mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sirico, M., D\u2019Angelo, A., Gianni, C., Casadei, C., Merloni, F., and De Giorgi, U. (2023). Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy. Cancers, 15.","DOI":"10.3390\/cancers15030703"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: Mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/2159-8290.CD-13-0063","article-title":"What a tangled web we weave: Emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway","volume":"3","author":"Klempner","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Czarnecka, A.M., Bartnik, E., Fiedorowicz, M., and Rutkowski, P. (2020). Targeted Therapy in Melanoma and Mechanisms of Resistance. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21134576"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"954","DOI":"10.18632\/oncotarget.652","article-title":"Mutations and deregulation of Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascades which alter therapy response","volume":"3","author":"McCubrey","year":"2012","journal-title":"Oncotarget"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/0008-5472.CAN-08-4765","article-title":"PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers","volume":"69","author":"Wee","year":"2009","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Wright, S.C.E., Vasilevski, N., Serra, V., Rodon, J., and Eichhorn, P.J.A. (2021). Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. Cancers, 13.","DOI":"10.3390\/cancers13071538"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1158\/1078-0432.CCR-17-3674","article-title":"ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy","volume":"24","author":"Jaiswal","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ccell.2015.11.011","article-title":"Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression","volume":"29","author":"Hayes","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1158\/0008-5472.CAN-14-1854","article-title":"Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer","volume":"75","author":"Pettazzoni","year":"2015","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.18632\/oncotarget.28759","article-title":"PCAIs stimulate MAPK, PI3K\/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast cancer cells while disrupting actin filaments and focal adhesion","volume":"16","author":"Lazarte","year":"2025","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100240","DOI":"10.1016\/j.mcpro.2022.100240","article-title":"eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors","volume":"21","author":"Hijazi","year":"2022","journal-title":"Mol. Cell Proteom."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Atanasova, V.S., Riedl, A., Strobl, M., Flandorfer, J., Unterleuthner, D., Weindorfer, C., Neuhold, P., Stang, S., Hengstschlager, M., and Bergmann, M. (2023). Selective Eradication of Colon Cancer Cells Harboring PI3K and\/or MAPK Pathway Mutations in 3D Culture by Combined PI3K\/AKT\/mTOR Pathway and MEK Inhibition. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021668"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev-biochem-060614-034402","article-title":"A structural perspective on the regulation of the epidermal growth factor receptor","volume":"84","author":"Kovacs","year":"2015","journal-title":"Annu. Rev. Biochem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-019-0099-9","article-title":"The emerging treatment landscape of targeted therapy in non-small-cell lung cancer","volume":"4","author":"Yuan","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1023\/A:1008209720526","article-title":"Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials","volume":"8","author":"Voldborg","year":"1997","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hsu, P.C., Jablons, D.M., Yang, C.T., and You, L. (2019). Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20153821"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1101\/gad.989602","article-title":"When cell biology meets development: Endocytic regulation of signaling pathways","volume":"16","author":"Seto","year":"2002","journal-title":"Genes. Dev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Janani, B., Vijayakumar, M., Priya, K., Kim, J.H., Prabakaran, D.S., Shahid, M., Al-Ghamdi, S., Alsaidan, M., Othman Bahakim, N., and Hassan Abdelzaher, M. (2022). EGFR-Based Targeted Therapy for Colorectal Cancer-Promises and Challenges. Vaccines, 10.","DOI":"10.3390\/vaccines10040499"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Jung, S., Kim, D.H., Choi, Y.J., Kim, S.Y., Park, H., Lee, H., Choi, C.M., Sung, Y.H., Lee, J.C., and Rho, J.K. (2021). Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-99267-z"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12943-018-0793-1","article-title":"EGFR-TKIs resistance via EGFR-independent signaling pathways","volume":"17","author":"Liu","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1007\/s12325-023-02680-1","article-title":"Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion","volume":"40","author":"Patel","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"107177","DOI":"10.1016\/j.lungcan.2023.107177","article-title":"Real-world treatment patterns and outcomes of patients with metastatic nonsquamous non-small cell lung cancer after progression on standard-of-care therapy in the United States","volume":"179","author":"Divan","year":"2023","journal-title":"Lung Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2022.05.011","article-title":"Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies","volume":"170","author":"Johnson","year":"2022","journal-title":"Lung Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/jjco\/hyad052","article-title":"Current treatment strategies for EGFR-mutated non-small cell lung cancer: From first line to beyond osimertinib resistance","volume":"53","author":"Araki","year":"2023","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1158\/1078-0432.CCR-22-3901","article-title":"BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer","volume":"29","author":"Lim","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Yan, H., Tang, S., Tang, S., Zhang, J., Guo, H., Qin, C., Hu, H., Zhong, C., Yang, L., and Zhu, Y. (2022). miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.949566"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/1061186X.2024.2449495","article-title":"Epidermal growth factor receptors unveiled: A comprehensive survey on mutations, clinical insights of global inhibitors, and emergence of heterocyclic derivatives as EGFR inhibitors","volume":"33","author":"Manojmouli","year":"2025","journal-title":"J. Drug Target."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Dickerson, H., Diab, A., and Al Musaimi, O. (2024). Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251810008"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Shaban, N., Kamashev, D., Emelianova, A., and Buzdin, A. (2023). Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications. Cells, 13.","DOI":"10.3390\/cells13010047"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/14728222.2023.2218613","article-title":"Targeting the EGFR signaling pathway in cancer therapy: What\u2019s new in 2023?","volume":"27","author":"Halder","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zheng, J., Zhang, W., Li, L., He, Y., Wei, Y., Dang, Y., Nie, S., and Guo, Z. (2022). Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review. Front. Chem., 10.","DOI":"10.3389\/fchem.2022.860985"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Alberca-Del Arco, F., Prieto-Cuadra, D., Santos-Perez de la Blanca, R., Saez-Barranquero, F., Matas-Rico, E., and Herrera-Imbroda, B. (2024). New Perspectives on the Role of Liquid Biopsy in Bladder Cancer: Applicability to Precision Medicine. Cancers, 16.","DOI":"10.3390\/cancers16040803"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Andreozzi, F., Dragani, M., Quivoron, C., Le Bras, F., Assi, T., Danu, A., Belhadj, K., Lazarovici, J., Cotteret, S., and Bernard, O.A. (2023). Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study. Cancers, 15.","DOI":"10.3390\/cancers15051508"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"490","DOI":"10.20892\/j.issn.2095-3941.2023.0137","article-title":"Current progress in cancer treatment by targeting FGFR signaling","volume":"20","author":"Du","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Benjamin, D.J., and Hsu, R. (2023). Treatment approaches for FGFR-altered urothelial carcinoma: Targeted therapies and immunotherapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1258388"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Xiao, J.F., Caliri, A.W., Duex, J.E., and Theodorescu, D. (2021). Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling. Cancers, 13.","DOI":"10.3390\/cancers13194891"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1200\/JCO.21.02303","article-title":"FORT-1: Phase II\/III Study of Rogaratinib Versus Chemotherapy in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1\/3 mRNA Expression","volume":"41","author":"Sternberg","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: Clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_49","first-page":"543","article-title":"Emerging RAS-directed therapies for cancer","volume":"4","author":"Conroy","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-13-1762","article-title":"A RAS renaissance: Emerging targeted therapies for KRAS-mutated non-small cell lung cancer","volume":"20","author":"Vasan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-021-01127-w","article-title":"Emerging strategies to target RAS signaling in human cancer therapy","volume":"14","author":"Chen","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1002\/mco2.285","article-title":"RAS-targeted cancer therapy: Advances in drugging specific mutations","volume":"4","author":"Liu","year":"2023","journal-title":"MedComm"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Tatli, O., and Dinler Doganay, G. (2021). Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy. Molecules, 26.","DOI":"10.3390\/molecules26247561"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1158\/1078-0432.CCR-21-2138","article-title":"Molecular Pathways and Mechanisms of BRAF in Cancer Therapy","volume":"28","author":"Poulikakos","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jviscsurg.2021.04.002","article-title":"Therapeutic implications of B-RAF mutations in colorectal cancer","volume":"158","author":"Lebrun","year":"2021","journal-title":"J. Visc. Surg."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e389574","DOI":"10.1200\/EDBK_389574","article-title":"Update on Emerging Therapies for Advanced Colorectal Cancer","volume":"43","author":"Alese","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1535370220959657","article-title":"Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database","volume":"246","author":"Owsley","year":"2021","journal-title":"Exp Biol Med"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Laha, D., Nilubol, N., and Boufraqech, M. (2020). New Therapies for Advanced Thyroid Cancer. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00082"},{"key":"ref_59","first-page":"426","article-title":"Fulfilling the potential of traditional birth attendants","volume":"9","author":"Okubagzhi","year":"1988","journal-title":"World Health Forum"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.pharmthera.2013.10.001","article-title":"MEK in cancer and cancer therapy","volume":"141","author":"Neuzillet","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/j.wneu.2023.08.137","article-title":"Case Report: Successful Use of BRAF\/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma","volume":"180","author":"Wu","year":"2023","journal-title":"World Neurosurg."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/cncr.32996","article-title":"MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers","volume":"126","author":"Gu","year":"2020","journal-title":"Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.trecan.2020.05.009","article-title":"Clinical Development of BRAF plus MEK Inhibitor Combinations","volume":"6","author":"Subbiah","year":"2020","journal-title":"Trends Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2016.04.005","article-title":"Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?","volume":"62","author":"Welsh","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"113354","DOI":"10.1016\/j.ejca.2023.113354","article-title":"Long-term outcomes and persistent toxicities following BRAF\/MEK inhibitor therapy for advanced melanoma","volume":"194","author":"Goodman","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2022.07.076","article-title":"Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts with Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer","volume":"163","author":"Datta","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s11912-024-01599-2","article-title":"Risk Stratification, Screening and Treatment of BRAF\/MEK Inhibitors-Associated Cardiotoxicity","volume":"26","author":"Senechal","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/IAE.0000000000002451","article-title":"Ocular Adverse Events Associated with Mek Inhibitors","volume":"39","author":"Calvo","year":"2019","journal-title":"Retina"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1159\/000539374","article-title":"Cutaneous Reactions in Pediatric Patients Treated with MEK Inhibitors: A Retrospective Single-Center Study","volume":"240","author":"Friedland","year":"2024","journal-title":"Dermatology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.2217\/fon.15.265","article-title":"Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: A comparative systematic review and meta-analysis","volume":"11","author":"ElHalawani","year":"2015","journal-title":"Future Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1093\/oncolo\/oyae014","article-title":"Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation","volume":"29","author":"Miller","year":"2024","journal-title":"Oncologist"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e000491","DOI":"10.1136\/esmoopen-2019-000491","article-title":"Tolerability of BRAF\/MEK inhibitor combinations: Adverse event evaluation and management","volume":"4","author":"Heinzerling","year":"2019","journal-title":"ESMO Open"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/CMR.0000000000000618","article-title":"Severe gastrointestinal toxicity of MEK inhibitors","volume":"29","author":"Mourad","year":"2019","journal-title":"Melanoma Res."},{"key":"ref_74","first-page":"610","article-title":"Mucocutaneous toxicities from MEK inhibitors: A scoping review of the literature","volume":"32","author":"Iriarte","year":"2024","journal-title":"Support. Care Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Garutti, M., Bergnach, M., Polesel, J., Palmero, L., Pizzichetta, M.A., and Puglisi, F. (2022). BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis. Cancers, 15.","DOI":"10.3390\/cancers15010141"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Li, Q., Li, Z., Luo, T., and Shi, H. (2022). Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy. Mol. Biomed., 3.","DOI":"10.1186\/s43556-022-00110-2"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/onc.2010.626","article-title":"PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer","volume":"30","author":"Serra","year":"2011","journal-title":"Oncogene"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2147\/OTT.S118366","article-title":"MicroRNA 543 suppresses breast cancer cell proliferation, blocks cell cycle and induces cell apoptosis via direct targeting of ERK\/MAPK","volume":"10","author":"Chen","year":"2017","journal-title":"Onco. Targets Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.18632\/oncotarget.1962","article-title":"HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib small compound","volume":"5","author":"Ramirez","year":"2014","journal-title":"Oncotarget"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.1158\/0008-5472.CAN-05-0216","article-title":"Prostaglandin E2 activates mitogen-activated protein kinase\/ERK pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner","volume":"65","author":"Krysan","year":"2005","journal-title":"Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Huang, Y., Zhen, Y., Chen, Y., Sui, S., and Zhang, L. (2023). Unraveling the interplay between RAS\/RAF\/MEK\/ERK signaling pathway and autophagy in cancer: From molecular mechanisms to targeted therapy. Biochem. Pharmacol., 217.","DOI":"10.1016\/j.bcp.2023.115842"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Zhang, M., Bai, Y., Xu, C., Qi, Y., Meng, J., Zhang, W., Su, H., and Yan, W. (2021). Blockage of Extracellular Signal-Regulated Kinase Exerts an Antitumor Effect via Regulating Energy Metabolism and Enhances the Efficacy of Autophagy Inhibitors by Regulating Transcription Factor EB Nuclear Translocation in Osteosarcoma. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.650846"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.apsb.2021.12.022","article-title":"Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy","volume":"12","author":"Pan","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1158\/2159-8290.CD-17-1355","article-title":"ERK Inhibition: A New Front in the War against MAPK Pathway-Driven Cancers?","volume":"8","author":"Smalley","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"13561","DOI":"10.1021\/acs.jmedchem.2c01244","article-title":"Targeting Extracellular Signal-Regulated Protein Kinase 1\/2 (ERK1\/2) in Cancer: An Update on Pharmacological Small-Molecule Inhibitors","volume":"65","author":"Fu","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10637-020-01035-9","article-title":"Characterization and management of ERK inhibitor associated dermatologic adverse events: Analysis from a nonrandomized trial of ulixertinib for advanced cancers","volume":"39","author":"Wu","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.phrs.2019.03.019","article-title":"Corrigendum to Targeting ERK1\/2 protein-serine\/threonine kinases in human cancers [Pharmcol. Res. 142 (2019) 151\u2013168]","volume":"143","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/toxsci\/kfab033","article-title":"Investigation Into the Role of ERK in Tyrosine Kinase Inhibitor-Induced Neuropathy","volume":"181","author":"Belair","year":"2021","journal-title":"Toxicol. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","article-title":"The present and future of PI3K inhibitors for cancer therapy","volume":"2","author":"Castel","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Zhang, Z., and Richmond, A. (2021). The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined with Immune Checkpoint Inhibitors. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.648663"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00204-023-03440-4","article-title":"Development and safety of PI3K inhibitors in cancer","volume":"97","author":"Yu","year":"2023","journal-title":"Arch. Toxicol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s40265-019-01161-6","article-title":"Alpelisib: First Global Approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/13543776.2024.2338100","article-title":"Targeting the PI3K\/AKT signaling pathway in anticancer research: A recent update on inhibitor design and clinical trials (2020\u20132023)","volume":"34","author":"Sabbah","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1146\/annurev-med-062913-051343","article-title":"The PI3K\/AKT Pathway as a Target for Cancer Treatment","volume":"67","author":"Mayer","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","article-title":"Management of toxicity to isoform alpha-specific PI3K inhibitors","volume":"30","author":"Nunnery","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jamaoncol.2019.0034","article-title":"Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients with Cancer: A Review","volume":"5","author":"Esposito","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/hematology.2020000119","article-title":"Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors","volume":"2020","author":"Hanlon","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14740338.2024.2387317","article-title":"Post-marketing safety concern of PI3K inhibitors in the cancer therapies: An 8-year disproportionality analysis from the FDA Adverse Event Reporting System","volume":"24","author":"Lin","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10549-020-05618-1","article-title":"Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer","volume":"181","author":"Drullinsky","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/13543784.2019.1676726","article-title":"Targeting AKT for cancer therapy","volume":"28","author":"Shariati","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2174\/1568009611313030002","article-title":"Diverse mechanisms of AKT pathway activation in human malignancy","volume":"13","author":"Cheung","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB Signaling: Navigating the Network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-021-01137-8","article-title":"Targeting AKT in cancer for precision therapy","volume":"14","author":"Hua","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/0008-5472.CAN-18-2738","article-title":"AKT as a Therapeutic Target for Cancer","volume":"79","author":"Song","year":"2019","journal-title":"Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Martorana, F., Motta, G., Pavone, G., Motta, L., Stella, S., Vitale, S.R., Manzella, L., and Vigneri, P. (2021). AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.662232"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","article-title":"Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease","volume":"8","author":"Panwar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Tian, T., Li, X., and Zhang, J. (2019). mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030755"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Peng, Y., Wang, Y., Zhou, C., Mei, W., and Zeng, C. (2022). PI3K\/Akt\/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.819128"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s12253-016-0066-5","article-title":"The Gene Expression Status of the PI3K\/AKT\/mTOR Pathway in Gastric Cancer Tissues and Cell Lines","volume":"22","author":"Riquelme","year":"2016","journal-title":"Pathol. Oncol. Res."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Singh, S., Barik, D., Lawrie, K., Mohapatra, I., Prasad, S., Naqvi, A.R., Singh, A., and Singh, G. (2023). Unveiling Novel Avenues in mTOR-Targeted Therapeutics: Advancements in Glioblastoma Treatment. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914960"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Conciatori, F., Ciuffreda, L., Bazzichetto, C., Falcone, I., Pilotto, S., Bria, E., Cognetti, F., and Milella, M. (2018). mTOR Cross-Talk in Cancer and Potential for Combination Therapy. Cancers, 10.","DOI":"10.3390\/cancers10010023"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12154-008-0003-5","article-title":"Rapamycin and mTOR kinase inhibitors","volume":"1","author":"Ballou","year":"2008","journal-title":"J. Chem. Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"101609","DOI":"10.1016\/j.esmoop.2023.101609","article-title":"Everolimus in combination with vandetanib in children, adolescents, and young adults: A phase I study","volume":"8","author":"Phadnis","year":"2023","journal-title":"ESMO Open"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.21873\/anticanres.16360","article-title":"A Phase I\/II Investigation of Safety and Efficacy of Nivolumab and nab-Sirolimus in Patients with a Variety of Tumors with Genetic Mutations in the mTOR Pathway","volume":"43","author":"Gordon","year":"2023","journal-title":"Anticancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.1158\/1078-0432.CCR-21-4290","article-title":"A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck","volume":"28","author":"Nathan","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1158\/1078-0432.CCR-20-4548","article-title":"Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations","volume":"27","author":"Adib","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00280-020-04183-0","article-title":"A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors","volume":"87","author":"Park","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1158\/1535-7163.MCT-15-0365","article-title":"AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules","volume":"14","author":"Guichard","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamaoncol.2022.7966","article-title":"Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs. Paclitaxel Alone in Patients with Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial","volume":"9","author":"Banerjee","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1158\/1078-0432.CCR-20-3242","article-title":"Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K\/mTOR Inhibitor","volume":"27","author":"Hong","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"a005041","DOI":"10.1101\/mcs.a005041","article-title":"Dual inhibition of BRAF and mTOR in BRAF (V600E)-mutant pediatric, adolescent, and young adult brain tumors","volume":"6","author":"Sen","year":"2020","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.oraloncology.2012.11.008","article-title":"A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients","volume":"49","author":"Martins","year":"2013","journal-title":"Oral Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2146\/ajhp100020","article-title":"Mammalian target of rapamycin: Biological function and target for novel anticancer agents","volume":"67","author":"Borders","year":"2010","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.tibs.2014.02.006","article-title":"PTEN function: The long and the short of it","volume":"39","author":"Hopkins","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fendo.2018.00338","article-title":"PTEN: Tumor Suppressor and Metabolic Regulator","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Luongo, F., Colonna, F., Calapa, F., Vitale, S., Fiori, M.E., and De Maria, R. (2019). PTEN Tumor-Suppressor: The Dam of Stemness in Cancer. Cancers, 11.","DOI":"10.3390\/cancers11081076"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Fusco, N., Sajjadi, E., Venetis, K., Gaudioso, G., Lopez, G., Corti, C., Rocco, E.G., Criscitiello, C., Malapelle, U., and Invernizzi, M. (2020). PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?. Genes, 11.","DOI":"10.3390\/genes11070719"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Alfieri, R., Giovannetti, E., Bonelli, M., and Cavazzoni, A. (2017). New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN\/Focal Adhesion Kinase Pathway. Front. Oncol., 7.","DOI":"10.3389\/fonc.2017.00170"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/cncr.35238","article-title":"FDA approves capivasertib with fulvestrant for breast cancer","volume":"130","author":"Nierengarten","year":"2024","journal-title":"Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00130","article-title":"Exceptional Response to AKT Inhibition in Patients with Breast Cancer and Germline PTEN Mutations","volume":"3","author":"Kingston","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e823","DOI":"10.1093\/oncolo\/oyad059","article-title":"AZD8186 in Combination with Paclitaxel in Patients with Advanced Gastric Cancer: Results from a Phase Ib\/II Study (KCSG ST18-20)","volume":"28","author":"Suh","year":"2023","journal-title":"Oncologist"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.gendis.2022.12.015","article-title":"Synthetic lethal approaches to target cancers with loss of PTEN function","volume":"10","author":"Ertay","year":"2023","journal-title":"Genes. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Pulido, R. (2018). PTEN Inhibition in Human Disease Therapy. Molecules, 23.","DOI":"10.3390\/molecules23020285"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1172\/JCI40535","article-title":"A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis","volume":"120","author":"Alimonti","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/15384101.2016.1138183","article-title":"A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells","volume":"15","author":"Augello","year":"2016","journal-title":"Cell Cycle"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/17\/8696\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:41:16Z","timestamp":1760035276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/17\/8696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,6]]},"references-count":140,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijms26178696"],"URL":"https:\/\/doi.org\/10.3390\/ijms26178696","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,6]]}}}